The newest reporting from every desk, ordered by publication time. New stories appear here immediately after publication.
A randomized trial found selective cognitive benefits from exercise coaching without significant advantages on its two primary outcomes. A companion analysis reported changes in aging biomarkers, whose long-term clinical meaning remains uncertain.
A new study identifies a molecular pathway connecting exercise-related blood signals with cartilage health. Human blood samples informed the research, but therapeutic benefits remain untested in patients.
The experimental eloralintide–tirzepatide combination produced encouraging sponsor-reported results in adults with type 2 diabetes. Treatment discontinuations and the analysis assumptions remain central to interpreting the findings.
Newly released TRIUMPH-2 findings strengthen evidence for the investigational drug in adults with excess weight and type 2 diabetes. Different statistical analyses yield different weight-loss estimates, while long-term health benefits remain unresolved.
New research complicates the assumption that cellular recycling uniformly declines with age. Its preliminary findings also highlight why measuring biological activity does not automatically establish a health benefit.
The announcement marks the platform’s entry into human testing. The candidate and trial details remain undisclosed, and no human results were released.
A September 28 research update highlights a small randomized trial of noninvasive stimulation for uncontrolled hypertension. A possible benefit in a small subgroup remains preliminary.
Researchers developed EHR-AGE using diagnosis histories from Hungary’s population records. The findings support further study of an accessible aging measure, while its value for clinical decisions remains unestablished.
Laboratory findings suggest a possible role alongside radiation, but tumor selectivity and patient benefit remain unestablished.
A randomized study in older adults separates a biochemical response from evidence of functional benefit. The findings leave broader healthy-aging claims unresolved.
A small observational study linked faster epigenetic aging in participants in their forties to later everyday memory complaints. The study found no significant overall association across the sample and does not establish a dementia screening test.
A September 23 update describes plans to advance RP001v63 toward human testing. FDA records confirm an August designation, while clinical safety and benefit remain unestablished.